Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The phosphatidylinositol 3-kinase (PI3K) pathway, including Akt and mammalian target of rapamycin (mTOR), is integral to cancer development.
• This pathway's role in malignant transformation, growth, proliferation, and metastasis makes it a key therapeutic target.

Purpose of the Study:

• To review the PI3K/Akt/mTOR pathway's significance in cancer.
• To discuss the rationale for targeting this pathway therapeutically.
• To summarize the clinical development progress of PI3K/Akt/mTOR inhibitors.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of drug development pipelines for PI3K/Akt/mTOR inhibitors.
• Discussion of emerging strategies including patient selection and combination therapies.

Main Results:

• Early PI3K/Akt/mTOR inhibitors demonstrated limited single-agent efficacy.
• Development is shifting towards more specific inhibitors and targeted patient populations.
• Combinational approaches are being explored to enhance therapeutic outcomes.

Conclusions:

• The PI3K/Akt/mTOR pathway remains a critical target in oncology.
• Advancements in inhibitor specificity and combination strategies are essential for clinical success.
• Further research is needed to optimize treatment regimens and overcome resistance mechanisms.